Check out my opinion piece on the FDA’s guidance for underrepresented groups in clincial studies that I wrote with Dr. Arthur Lazarus, published in MedPage Today.
While comprehensive and well-intentioned, its implementation may pose challenges, particularly for smaller sponsors. Enhancements in clarity, support for implementation, and enforcement mechanisms could further strengthen its impact.